The Middle East Life Science Market is driven by rising disease burden, better diagnostics, and growing R&D. The U.A.E. leads the region, while Saudi Arabia, Egypt, and Turkey advance in precision medicine. Core technologies like PCR, d-PCR, NGS, cell culture, and western blotting are propelling growth, with tools like Illumina’s NovaSeq and MiSeq supporting major genomics projects. Despite challenges in talent and tech adoption, post-COVID awareness is accelerating molecular diagnostics across MENA.
• According to BIS Research, the Middle East RT-PCR market was valued at $144.5 million in 2021 and is projected to reach $596.2 million by 2032, growing at a CAGR of 13.78%. Widely used in clinical diagnostics, especially during the COVID-19 pandemic, major players include G42 Healthcare and Thermo Fisher Scientific.
• In the Middle East PCR market, the valuation stood at $273.6 million in 2021 and is expected to rise to $813.1 million by 2032, at a CAGR of 10.27%. This segment is dominated by conventional and RT-PCR technologies, bolstered by collaborations like G42-BGI for COVID-19 testing.
• The Middle East digital PCR (d-PCR) market is emerging, valued at $15.6 million in 2021 and projected to reach $73.7 million by 2032 with a CAGR of 15.19%. Bio-Rad Laboratories and QIAGEN are the leading contributors, though adoption remains limited in labs.
• According to BIS Research, the Middle East NGS market was valued at $215.6 million in 2021 and is expected to grow to $1,285.8 million by 2032, with a strong CAGR of 15.71%. Illumina and Thermo Fisher Scientific lead this space, driven by national genome projects like the Emirati and Qatar Genome Projects.
• The Middle East cell culture market reached $237.5 million in 2021 and is forecasted to grow to $561.9 million by 2032 at a CAGR of 7.74%, with GE Healthcare and Thermo Fisher Scientific playing dominant roles in biopharma and academic research.
• In the Middle East western blotting market, the 2021 valuation was $44.9 million, projected to increase to $93.2 million by 2032 at a CAGR of 6.57%. Bio-Rad Laboratories and Cleaver Scientific are key players in this segment.
Need more details on Market Growth and Competitors Download Sample Report
The Middle East life sciences market is growing rapidly, driven by government-backed genomic research, rising biopharma R&D, and increased adoption of NGS and digital PCR. COVID-19 boosted RT-PCR and d-PCR use for viral detection. Public-private projects like the Emirati and Saudi Genome Projects, along with digital tools like AI and LIMS, are accelerating innovation and efficiency.
Access Market Insights on Middle East Life Science Market
Growth is hindered by a shortage of skilled professionals, delayed adoption of advanced molecular diagnostics, and the high cost of technologies like NGS sequencers and d-PCR instruments, limiting access for smaller laboratories.
Key trends include the rise of population genomics through projects like the U.A.E. Genome Project, adoption of digital research tools, and expansion in biopharmaceutical R&D, especially in cell culture and proteomics. Innovation in cost-effective, high-throughput diagnostic technologies is also gaining momentum, transforming clinical diagnostics across the region.
The Middle East life sciences market is set for strong growth, driven by advances in genomics, proteomics, and precision medicine. Strategic investments and digital transformation are helping the region overcome workforce and logistical challenges, positioning it as a rising global hub for life sciences innovation.
Explore BIS Research’s tailored Go-to-Market Strategy that help businesses explore and enter emerging markets, promising professional guidance to unlock new opportunities.
